Masuda M, Sukehiro S, Möllhoff T, Van Belle H, Flameng W
Laboratory of Experimental Cardiac Surgery, Katholieke Universiteit Leuven, Belgium.
Arch Int Pharmacodyn Ther. 1993 Mar-Apr;322:45-54.
The effect of nucleoside transport inhibition on the adenylate catabolism was studied in the human myocardium under normothermic ischemic conditions. Ten hearts from cardiac transplant recipients and two hearts from cardiac homograft donors were used in this study. The hearts were excised under hypothermic conditions (25 degrees C body temperature), the coronary arteries flushed with 500 ml ice-cold Ringer solution (n = 6; group I) or with ice-cold Ringer solution containing 1 mg/l of the nucleoside transport inhibitor R75231 (n = 6; group II). After transportation at 0 degree C from the operation room, the hearts were quickly rewarmed to 37 degrees C. Serial transmural biopsy specimens were taken during normothermic ischemia for determination of purine catabolites. The level of ATP before normothermic ischemia was 17.5 +/- 1.0 mumol/g dry weight in the control group (group I) and 19.3 +/- 0.4 mumol/g dry weight in the drug group. ATP, expressed as percentage of total purine content, was similar in both groups before rewarming (79.5 +/- 4.3% in group I and 79.5 +/- 2.9% in group II). There was no significant difference in the rate of ATP breakdown in both groups throughout the experiment (ATP was 3.0 +/- 1.4% of total purines in group I and 1.4 +/- 0.2% in group II at 120 min of normothermic ischemia). Adenine nucleotide content changed also similarly in both groups. Adenosine accumulation was, however, significantly higher in group II than in group I (peak values: 4.6 +/- 1.0% of total purines in group I vs 14.0 +/- 1.7% in group II; p < 0.01). The ratio between adenosine and inosine was significantly higher in group II throughout normothermic ischemia (p < 0.01). In spite of a larger accumulation of adenosine in group II, the increase in inosine was similar in both groups. We conclude that nucleoside transport inhibition significantly delays the breakdown of adenosine and the formation of hypoxanthine in the ischemic human myocardium.
在常温缺血条件下,研究了核苷转运抑制对人心肌中腺苷酸分解代谢的影响。本研究使用了来自心脏移植受者的10颗心脏和来自心脏同种异体移植供者的2颗心脏。在低温条件下(体温25℃)切除心脏,冠状动脉用500ml冰冷的林格溶液冲洗(n = 6;I组)或用含1mg/l核苷转运抑制剂R75231的冰冷林格溶液冲洗(n = 6;II组)。在0℃从手术室转运后,心脏迅速复温至37℃。在常温缺血期间采集系列透壁活检标本以测定嘌呤分解代谢产物。常温缺血前对照组(I组)ATP水平为17.5±1.0μmol/g干重,药物组为19.3±0.4μmol/g干重。复温前两组中以总嘌呤含量百分比表示的ATP相似(I组为79.5±4.3%,II组为79.5±2.9%)。在整个实验过程中两组ATP分解速率无显著差异(常温缺血120分钟时,I组ATP占总嘌呤的3.0±1.4%,II组为1.4±0.2%)。两组中腺嘌呤核苷酸含量变化也相似。然而,II组中腺苷积累显著高于I组(峰值:I组为总嘌呤的4.6±1.0%,II组为14.0±1.7%;p<0.01)。在整个常温缺血期间II组中腺苷与肌苷的比率显著更高(p<0.01)。尽管II组中腺苷积累更多,但两组中肌苷的增加相似。我们得出结论,核苷转运抑制显著延迟了缺血人心肌中腺苷的分解和次黄嘌呤的形成。